Handa Pharmaceuticals (Taiwan) Performance
| 6620 Stock | TWD 54.60 2.10 3.70% |
The company retains a Market Volatility (i.e., Beta) of -0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Handa Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Handa Pharmaceuticals is likely to outperform the market. At this point, Handa Pharmaceuticals has a negative expected return of -0.67%. Please make sure to check out Handa Pharmaceuticals' jensen alpha, treynor ratio, and the relationship between the information ratio and total risk alpha , to decide if Handa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Handa Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Quick Ratio | 9.05 | |
| Fifty Two Week Low | 21.00 | |
| Fifty Two Week High | 55.70 |
Handa |
Handa Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 8,420 in Handa Pharmaceuticals on August 30, 2024 and sell it today you would lose (2,960) from holding Handa Pharmaceuticals or give up 35.15% of portfolio value over 90 days. Handa Pharmaceuticals is generating negative expected returns and assumes 2.3513% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than Handa, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Handa Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Handa Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Handa Pharmaceuticals, and traders can use it to determine the average amount a Handa Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2848
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6620 |
Estimated Market Risk
| 2.35 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.67 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.28 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Handa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Handa Pharmaceuticals by adding Handa Pharmaceuticals to a well-diversified portfolio.
Handa Pharmaceuticals Fundamentals Growth
Handa Stock prices reflect investors' perceptions of the future prospects and financial health of Handa Pharmaceuticals, and Handa Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Handa Stock performance.
| Return On Equity | -41.47 | |||
| Return On Asset | -27.2 | |||
| Current Valuation | 2.86 B | |||
| Shares Outstanding | 115.57 M | |||
| Price To Book | 8.38 X | |||
| Price To Sales | 196.22 X | |||
| Revenue | 28.86 M | |||
| EBITDA | (309.06 M) | |||
| Cash And Equivalents | 315.09 M | |||
| Cash Per Share | 2.72 X | |||
| Total Debt | 13.36 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 5.85 X | |||
| Cash Flow From Operations | (308.47 M) | |||
| Earnings Per Share | (2.29) X | |||
About Handa Pharmaceuticals Performance
Evaluating Handa Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Handa Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Handa Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company also develops modified release dosage forms, such as orally disintegrating tablets, modified release orally disintegrating tablets, modified release suspension systems, and ophthalmic modified release systems. HANDA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about Handa Pharmaceuticals performance evaluation
Checking the ongoing alerts about Handa Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Handa Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Handa Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the revenue of 28.86 M. Net Loss for the year was (282.1 M) with profit before overhead, payroll, taxes, and interest of 68.71 M. | |
| Handa Pharmaceuticals has accumulated about 315.09 M in cash with (308.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.72. |
- Analyzing Handa Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Handa Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Handa Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Handa Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Handa Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Handa Pharmaceuticals' stock. These opinions can provide insight into Handa Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Handa Stock Analysis
When running Handa Pharmaceuticals' price analysis, check to measure Handa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Handa Pharmaceuticals is operating at the current time. Most of Handa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Handa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Handa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Handa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.